» Articles » PMID: 35562538

Structure-based Assessment and Druggability Classification of Protein-protein Interaction Sites

Overview
Journal Sci Rep
Specialty Science
Date 2022 May 13
PMID 35562538
Authors
Affiliations
Soon will be listed here.
Abstract

The featureless interface formed by protein-protein interactions (PPIs) is notorious for being considered a difficult and poorly druggable target. However, recent advances have shown PPIs to be druggable, with the discovery of potent inhibitors and stabilizers, some of which are currently being clinically tested and approved for medical use. In this study, we assess the druggability of 12 commonly targeted PPIs using the computational tool, SiteMap. After evaluating 320 crystal structures, we find that the PPI binding sites have a wide range of druggability scores. This can be attributed to the unique structural and physiochemical features that influence their ligand binding and concomitantly, their druggability predictions. We then use these features to propose a specific classification system suitable for assessing PPI targets based on their druggability scores and measured binding-affinity. Interestingly, this system was able to distinguish between different PPIs and correctly categorize them into four classes (i.e. very druggable, druggable, moderately druggable, and difficult). We also studied the effects of protein flexibility on the computed druggability scores and found that protein conformational changes accompanying ligand binding in ligand-bound structures result in higher protein druggability scores due to more favorable structural features. Finally, the drug-likeness of many published PPI inhibitors was studied where it was found that the vast majority of the 221 ligands considered here, including orally tested/marketed drugs, violate the currently acceptable limits of compound size and hydrophobicity parameters. This outcome, combined with the lack of correlation observed between druggability and drug-likeness, reinforces the need to redefine drug-likeness for PPI drugs. This work proposes a PPI-specific classification scheme that will assist researchers in assessing the druggability and identifying inhibitors of the PPI interface.

Citing Articles

Identification of Structurally Novel KRAS Inhibitors through Covalent DNA-Encoded Library Screening.

Huang D, Manoni F, Sun Z, Liu R, Allen J, Banerjee A J Med Chem. 2025; 68(4):4801-4817.

PMID: 39930787 PMC: 11873997. DOI: 10.1021/acs.jmedchem.4c03071.


Biological Implications of the Intrinsic Deformability of Human Acetylcholinesterase Induced by Diverse Compounds: A Computational Study.

Alvarado Y, Gonzalez-Paz L, Paz J, Lorono-Gonzalez M, Santiago Contreras J, Lossada C Biology (Basel). 2025; 13(12.

PMID: 39765732 PMC: 11672903. DOI: 10.3390/biology13121065.


A computational and machine learning approach to identify GPR40-targeting agonists for neurodegenerative disease treatment.

Siddiqui A, Badraoui R, Alshahrani M, Snoussi M, Jahan S, Siddiqui M PLoS One. 2024; 19(10):e0306579.

PMID: 39378198 PMC: 11481007. DOI: 10.1371/journal.pone.0306579.


Comparative analysis of adhesion virulence protein FadA from gut-associated bacteria of colorectal cancer patients () and healthy individuals ().

Hussain N, Muccee F, Ashraf N, Afsar T, Husain F, Hamid A J Cancer. 2024; 15(17):5492-5505.

PMID: 39308684 PMC: 11414602. DOI: 10.7150/jca.98951.


Potential Inhibitors of Lumpy Skin Disease's Viral Protein (DNA Polymerase): A Combination of Bioinformatics Approaches.

Zia S, Sumon M, Ashik M, Basar A, Lim S, Oh Y Animals (Basel). 2024; 14(9).

PMID: 38731287 PMC: 11083254. DOI: 10.3390/ani14091283.


References
1.
Gonzalez M, Kann M . Chapter 4: Protein interactions and disease. PLoS Comput Biol. 2013; 8(12):e1002819. PMC: 3531279. DOI: 10.1371/journal.pcbi.1002819. View

2.
Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

3.
Scott D, Bayly A, Abell C, Skidmore J . Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat Rev Drug Discov. 2016; 15(8):533-50. DOI: 10.1038/nrd.2016.29. View

4.
Cheng A, Coleman R, Smyth K, Cao Q, Soulard P, Caffrey D . Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol. 2007; 25(1):71-5. DOI: 10.1038/nbt1273. View

5.
Mabonga L, Kappo A . Protein-protein interaction modulators: advances, successes and remaining challenges. Biophys Rev. 2019; 11(4):559-581. PMC: 6682198. DOI: 10.1007/s12551-019-00570-x. View